Literature DB >> 24649128

Clinicopathological analysis of small-sized thymoma with podoplanin and Ki 67 expression analysis.

Keisuke Yokota1, Hisashi Tateyama2, Motoki Yano1, Satoru Moriyama1, Yu Hikosaka1, Katsuhiro Okuda1, Masayuki Shitara1, Meinoshin Okumura3, Kohei Yokoi4, Yoshitaka Fujii1.   

Abstract

Thymoma is the most common tumor of the anterior mediastinum for which surgical resection is currently the primary form of treatment. An increase in the incidence of a small-sized (≤3 cm) thymoma (SST) has recently been noted. Clinicopathological factors and prognosis of SST have not been reported previously. In this study, the clinicopathological data of 21 SST patients were reviewed and podoplanin and Ki67 immunohistochemistry were assessed to determine the biological behavior of SSTs. Pathological diagnosis of SSTs revealed the following types: A (n=1), AB (n=8), B1 (n=5), B2 (n=6) and B3 (n=1). The Masaoka-Koga stages of 21 thymoma patients were I (n=16), II (n=3), III (n=1) and IVb (n=1). In the case of the stage IVb thymoma, phrenic nerve, mediastinal pleura invasion and anterior mediastinal lymph node metastasis were observed. The Ki67 labeling index of this stage IVb was found to be 3.2. This case was also positive for podoplanin and was one of the only 2 cases that were positive for podoplanin. This patient succumbed to thymoma. Advanced stage thymomas are possibly included in SSTs although the majority of SSTs are classified into early stages of disease. Findings of this study suggest that podoplanin analyzed by immunohistochemistry may be useful to determine the malignant behavior of SSTs.

Entities:  

Keywords:  Ki67; podoplanin; small-sized; thymoma

Year:  2012        PMID: 24649128      PMCID: PMC3956257          DOI: 10.3892/mco.2012.2

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  18 in total

Review 1.  Standard outcome measures for thymic malignancies.

Authors:  James Huang; Frank C Detterbeck; Zuoheng Wang; Patrick J Loehrer
Journal:  J Thorac Oncol       Date:  2010-12       Impact factor: 15.609

2.  Expression of podoplanin in thymoma: its correlation with tumor invasion, nodal metastasis, and poor clinical outcome.

Authors:  Hisashi Tateyama; Hiroshi Sugiura; Chihiro Yamatani; Motoki Yano
Journal:  Hum Pathol       Date:  2011-01-14       Impact factor: 3.466

3.  Detection of bcl-2 and p53 in thymoma: expression of bcl-2 as a reliable marker of tumor aggressiveness.

Authors:  F F Chen; J J Yan; Y T Jin; I J Su
Journal:  Hum Pathol       Date:  1996-10       Impact factor: 3.466

4.  Cushing syndrome secondary to a thymic carcinoid tumor due to multiple endocrine neoplasia type 1.

Authors:  Ali A Ghazi; Azizollah Abbasi Dezfooli; Farzaneh Mohamadi; Seyed Vahid Yousefi; Alireza Amirbaigloo; Siavash Ghazi; Marina Pourafkari; Dan Berney; Sian Ellard; Ashley B Grossman
Journal:  Endocr Pract       Date:  2011 Jul-Aug       Impact factor: 3.443

Review 5.  Ki67 in breast cancer: prognostic and predictive potential.

Authors:  Rinat Yerushalmi; Ryan Woods; Peter M Ravdin; Malcolm M Hayes; Karen A Gelmon
Journal:  Lancet Oncol       Date:  2010-02       Impact factor: 41.316

6.  Long-term survival of thymoma patients by histologic pattern and proliferative activity.

Authors:  A Pich; R Chiarle; L Chiusa; R Ponti; M Geuna; C Casadio; G Maggi; G Palestro
Journal:  Am J Surg Pathol       Date:  1995-08       Impact factor: 6.394

7.  Thymic epithelial tumours: evaluation of malignant grade by quantification of proliferating cell nuclear antigen and nucleolar organizer regions.

Authors:  H Tateyama; T Mizuno; T Tada; T Eimoto; T Hashimoto; A Masaoka
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

8.  Limited thymectomy for stage I or II thymomas.

Authors:  Takuya Onuki; Shigemi Ishikawa; Kesato Iguchi; Yukinobu Goto; Mitsuaki Sakai; Masaharu Inagaki; Tatsuo Yamamoto; Masataka Onizuka; Yukio Sato; Kiyoshi Ohara; Yuzuru Sakakibara
Journal:  Lung Cancer       Date:  2009-08-29       Impact factor: 5.705

9.  Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan.

Authors:  Kazuya Kondo; Yasumasa Monden
Journal:  Ann Thorac Surg       Date:  2003-09       Impact factor: 4.330

10.  p53 protein expression and p53 gene mutation in thymic epithelial tumors. An immunohistochemical and DNA sequencing study.

Authors:  H Tateyama; T Eimoto; T Tada; T Mizuno; H Inagaki; A Hata; M Sasaki; A Masaoka
Journal:  Am J Clin Pathol       Date:  1995-10       Impact factor: 2.493

View more
  1 in total

1.  Bone morphogenetic protein-7 expression reflects the high proliferative ability and aggressiveness of thymic epithelial tumors.

Authors:  Kentaro Miura; Kazutoshi Hamanaka; Tsuyoshi Uehara; Masanobu Momose; Yukiko Kanai; Shunichiro Matsuoka; Tetsu Takeda; Hiroyuki Agatsuma; Akira Hyogotani; Ken-Ichi Ito
Journal:  J Thorac Dis       Date:  2020-03       Impact factor: 2.895

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.